Premium
Effect of Estriol on Bone Loss in Postmenopausal Japanese Women: A Multicenter Prospective Open Study
Author(s) -
Minaguchi Hiroshi,
Uemura Tsuguo,
Shirasu Kazuhiro,
Sato Akira,
Tsukikawa Susumu,
Ibuki Yoshito,
Mizunuma Hideki,
Aso Takeshi,
Koyama Takao,
Nozawa Shiro,
Ohta Hiroaki,
Ikeda Toshiyuki,
Kusuhara Koji,
Ochiai Kazuhiko,
Kato Junzo,
Kinoshita Toshihiko,
Tanaka Kenichi,
Minagawa Yusuke,
Kurabayashi Takumi,
Fukunaga Masao
Publication year - 1996
Publication title -
journal of obstetrics and gynaecology research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.597
H-Index - 50
eISSN - 1447-0756
pISSN - 1341-8076
DOI - 10.1111/j.1447-0756.1996.tb00976.x
Subject(s) - medicine , estriol , climacteric , bone remodeling , bone mineral , prospective cohort study , bone density , incidence (geometry) , urology , menopause , gynecology , osteoporosis , estrogen , physics , optics
Objectives: To assess the effects of oral estriol on the bone mineral density (BMD) and bone metabolism in postmenopausal women. Methods: Seventy‐five natural postmenopausal women with a BMD of more than 10% below the peak bone density were treated for 50 weeks with 2 mg/day estriol (E 3 ) cyclically and 0.8 g/day of calcium lactate continuously. BMDs at L 2 ‐L 4 were measured by dual energy X‐ray absorptiometry (DXA). Results: The BMD increased 1.79% (p < 0.01 vs. pretreatment) after 50 weeks, accompanied with decrease of biochemical markers of bone turnover. With regard to climacteric symptoms, Kupperman's menopausal index improved (p < 0.01 vs. pre‐treatment) after 5 weeks of treatment. As to the incidence of adverse events genital bleeding was observed in only 8.0% of the subjects. Endometrial histology and cytology showed neither abnormalities nor hyperplasia during and after the treatment. Conclusions: Estriol prevented postmenopausal bone loss and improved climacteric symptoms effectively with low incidence of genital bleeding.